Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Finke

Showing results (201-210 of 270) with videos related to

Pageof 27
Sort By:
Leukemia|April 15, 2005
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysisP Dreger, R Brand, D Milligan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 1997
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomasV Kolenko, Q Wang, M C Riedy, et al.
Cancer|March 17, 2001
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trialI Buchmann, M Reinhardt, K Elsner, et al.
Leukemia|May 17, 2003
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioningP Dreger, R Brand, J Hansz, et al.
Bone Marrow Transplantation|May 9, 2017
Partial break in tolerance of NKG2A<sup>-</sup>/LIR-1<sup>-</sup> single KIR<sup>+</sup> NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantationS Rathmann, C Keck, C Kreutz, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1996
Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancyT Olencki, J Finke, R Tubbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findingsR M Bukowski, T Olencki, H Gunn, et al.
Bone Marrow Transplantation|March 10, 2015
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working PartyK Horstmann, A Boumendil, J Finke, et al.
Human Gene Therapy|May 15, 1998
Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing mediumH Glimm, K Flügge, D Möbest, et al.
Bone Marrow Transplantation|April 8, 2009
Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMTP Chevallier, M Labopin, A Nagler, et al.
Pageof 27

Showing results (201-210 of 270) with videos related to

Sort By:
Pageof 27
Leukemia|April 15, 2005
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysisP Dreger, R Brand, D Milligan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 1997
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomasV Kolenko, Q Wang, M C Riedy, et al.
Cancer|March 17, 2001
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trialI Buchmann, M Reinhardt, K Elsner, et al.
Leukemia|May 17, 2003
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioningP Dreger, R Brand, J Hansz, et al.
Bone Marrow Transplantation|May 9, 2017
Partial break in tolerance of NKG2A<sup>-</sup>/LIR-1<sup>-</sup> single KIR<sup>+</sup> NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantationS Rathmann, C Keck, C Kreutz, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1996
Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancyT Olencki, J Finke, R Tubbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1996
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findingsR M Bukowski, T Olencki, H Gunn, et al.
Bone Marrow Transplantation|March 10, 2015
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working PartyK Horstmann, A Boumendil, J Finke, et al.
Human Gene Therapy|May 15, 1998
Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing mediumH Glimm, K Flügge, D Möbest, et al.
Bone Marrow Transplantation|April 8, 2009
Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMTP Chevallier, M Labopin, A Nagler, et al.
Pageof 27